Psychopharmacological Interventions

Child and Adolescent Psychiatric Clinics of North America

Volumn 17, Issue 2, 2008, Pages 439-458

  Biederman, Joseph ^a,b   Spencer, Thomas J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; FLUOXETINE; GUANFACINE; HYDRAZINE; IMIPRAMINE; LISDEXAMFETAMINE; METHYLPHENIDATE; MODAFINIL; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PHENELZINE; PLACEBO; TRANYLCYPROMINE; VENLAFAXINE;

ALTERNATIVE MEDICINE; ANOREXIA; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; BLISTER; BLOOD PRESSURE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; CONFUSION; DECREASED APPETITE; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DROWSINESS; DRUG FATALITY; DRUG WITHDRAWAL; EDEMA; ERYTHEMA; EXPECTATION; FAMILY; FATIGUE; HEADACHE; HEART RATE; HUMAN; HYPOTENSION; INSOMNIA; INTERVENTION STUDY; IRRITABILITY; LIVER INJURY; MEDICAL EDUCATION; MONOTHERAPY; NEUROBIOLOGY; NEUROLOGY; NOCTURIA; ORTHOSTATIC HYPOTENSION; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOPHARMACOLOGY; PULSE RATE; RASH; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SKIN PRURITUS; SKIN REDNESS; SKIN SWELLING; SOCIAL ASPECT; SOMNOLENCE; SYMPTOM; TIC; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR THERAPY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; LONG-TERM CARE; TREATMENT OUTCOME;

EID: 39149091731     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chc.2007.12.001     Document Type: Review

References (122)

1. Bymaster F.P., Katner J.S., Nelson D.L., et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27 (2002) 699-711
2. Volkow N.D., Wang G., Fowler J.S., et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21 (2001) RC121
3. Greenhill L., Halperin J., and Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry 38 (1998) 503-512
4. Pliszka S., and AACAP work group on quality issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46 (2007) 894-921
5. Spencer T., Biederman J., and Wilens T. Pharmacotherapy of ADHD: a life span perspective. In: Oldham J., and Riba M. (Eds). American psychiatric press review of psychiatry (1997), APA Press, Washington 87-128
6. Spencer T., Wilens T., Biederman J., et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 52 (1995) 434-443
7. Wilens T.E., Biederman J., Spencer T.J., et al. Controlled trial of high doses of pemoline for adults with attention- deficit/hyperactivity disorder. J Clin Psychopharmacol 19 (1999) 257-264
8. Barkley R.A. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 18 (1977) 137-165
9. Gittleman-Klein R. Pharmacotherapy of childhood hyperactivity: an update. In: Meltzer H.Y. (Ed). Psychopharmacology: the third generation of progress (1987), Raven Press, New York 1215-1224
10. Rapport M.D., Stoner G., DuPaul G.J., et al. Attention deficit disorder and methylphenidate: a multilevel analysis of dose-response effects on children's impulsivity across settings. J Am Acad Child Adolesc Psychiatry 27 (1988) 60-69
11. Bergman A., Winters L., and Cornblatt B. Methylphenidate: effects on sustained attention. In: Greenhill L., and Osman B. (Eds). Ritalin: theory and patient management (1991), Mary Ann Liebert, Inc., New York 223-231
12. Faraone S.V., Biederman J., Lehman B.K., et al. Intellectual performance and school failure in children with attention deficit hyperactivity disorder and in their siblings. J Abnorm Psychol 102 (1993) 616-623
13. Douglas V., Barr R., Amin K., et al. Dosage effects and individual responsivity to methylphenidate in attention deficit disorder. J Child Psychol Psychiatry 29 (1988) 453-475
14. Kupietz S.S., Winsberg B.G., Richardson E., et al. Effects of methylphenidate dosage in hyperactive reading-disabled children: I. Behavior and cognitive performance effects. J Am Acad Child Adolesc Psychiatry 27 (1988) 70-77
15. Pelham W.E., Bender M.E., Caddell J., et al. Methylphenidate and children with attention deficit disorder. Arch Gen Psychiatry 42 (1985) 948-952
16. Rapport M.D., DuPaul G.J., and Kelly K.L. Attention deficit hyperactivity disorder and methylphenidate: the relationship between gross body weight and drug response in children. Psychopharmacol Bull 25 (1989) 285-290
17. Rapport M.D., Jones J.T., DuPaul G.J., et al. Attention deficit disorder and methylphenidate: group and single-subject analyses of dose effects on attention in clinic and classroom settings. J Clin Child Psychol 16 (1987) 329-338
18. Rapport M.D., Quinn S.O., DuPaul G.J., et al. Attention deficit disorder with hyperactivity and methylphenidate: the effects of dose and mastery level on children's learning performance. J Abnorm Child Psychol 17 (1989) 669-689
19. Tannock R., Schachar R.J., Carr R.P., et al. Dose-response effects of methylphenidate on academic performance and overt behavior in hyperactive children. Pediatrics 84 (1989) 648-657
20. Jensen P.S., Arnold L.E., Swanson J.M., et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 46 (2007) 989-1002
21. Martins S., Tramontina S., Polanczyk G., et al. Weekend holidays with Methylphenidate use in ADHD children: a randomized clinical trial. J Child Adolesc Psychopharmacol 14 (2004) 195-206
22. Wilens T.E., and Biederman J. The stimulants. Psychiatr Clin North Am 15 1 (1992) 191-222
23. Barkley R.A., Murray M.B., Edelbrock C., et al. Side effects of methylphenidate in children with attention-deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 86 (1990) 184-192
24. Brown R.T., Wynne M.E., and Slimmer L.W. Attention deficit disorder and the effect of methylphenidate on attention, behavioral, and cardiovascular functioning. J Clin Psychiatry 45 (1984) 473-476
25. Lowe T.L., Cohen D.J., and Detlor J. Stimulant medications precipitate Tourette's syndrome. JAMA 247 (1982) 1168-1169
26. Comings D.E., and Comings B.G. Tourette's syndrome and attention deficit disorder. In: Cohen D.J., Bruun R.D., and Leckman J.F. (Eds). Tourette's syndrome and tic disorders: clinical understanding and treatment (1988), John Wiley and Sons, New York 119-136
27. Gadow K., Sverd J., Sprafkin J., et al. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 52 (1995) 444-455 [published erratum appears in Arch Gen Psychiatry 1995 Oct;52(10):836]
28. Gadow K.D., Nolan E.E., and Sverd J. Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short-term behavioral effects in school settings. J Am Acad Child Adolesc Psychiatry 31 (1992) 462-471
29. Spencer T., Biederman J., Coffey B., et al. The 4-year course of tic disorders in boys with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56 (1999) 842-847
30. Biederman J., Wilens T., Mick E., et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104 (1999) e20
31. Wilens T., McBurnett K., Stein M., et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 44 10 (2005) 1015-1023
32. Spencer T.J., Biederman J., Ciccone P.E., et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 163 (2006) 387-395
33. Faraone SV, Biederman J, Morley CP, et al. The effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry, in press.
34. Spencer T., Biederman J., and Wilens T. Growth deficits in children with attention deficit hyperactivity disorder. Pediatrics 102 (1998) 501-506
35. Pelham W.E., Gnagy E.M., Burrows-Maclean L., et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107 (2001) E105
36. Wolraich M., Greenhill L.L., Pelham W., et al. Randomized controlled trial of OROS methylphenidate qd in children with attention deficit/hyperactivity disorder. Pediatrics 108 (2001) 883-892
37. Palumbo D., Spencer T., Lynch J., et al. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol 14 2 (2004) 185-194
38. Spencer T.J., Faraone S.V., Biederman J., et al. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD?. J Am Acad Child Adolesc Psychiatry 45 5 (2006) 527-537
39. Greenhill L.L., Findling R.L., and Swanson J.M. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 109 (2002) E39
40. Biederman J., Quinn D., Weiss M., et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs 5 12 (2003) 833-841
41. McCracken J.T., Biederman J., Greenhill L.L., et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry 42 6 (2003) 673-683
42. Biederman J., Lopez F.A., Boellner S.W., et al. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 in children with attention deficit hyperactivity disorder. Pediatrics 110 (2002) 258-266
43. McGough J.J., Biederman J., Wigal S.B., et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry 44 6 (2005) 530-538
44. Wigal S., Swanson J.M., Feifel D., et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 43 11 (2004) 1406-1414
45. Arnold L.E., Lindsay R.L., Conners C.K., et al. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 14 4 (2004) 542-554
46. Greenhill L.L., Muniz R., Ball R.R., et al. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45 7 (2006) 817-823
47. Pelham W.E., Manos M.J., Ezzell C.E., et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 44 (2005) 522-529
48. Pelham W.E., Burrows-Maclean L., Gnagy E.M., et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol 13 (2005) 111-126
49. McGough J.J., Wigal S.B., Abikoff H., et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 9 (2006) 476-485
50. Findling R.L., Bukstein O.G., Melmed R.D., et al. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Methylphenidate Transdermal System in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder. J Clin Psychiatry (2008) in press
51. Biederman J., Boellner S.W., Childress A., et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 62 9 (2007) 970-976
52. Biederman J., Krishnan S., Zhang Y., et al. Efficacy and safety of Lisdexamfetamine (LDX; NRP104) in children with attention-deficit/hyperactivity disorder: a phase 3, randomized, multicenter, double-blind, parallel-group study. Clin Ther 29 (2007) 450-463
53. Gittleman R., et al. Childhood disorders. In: Klein D., Quitkin F., and Rifkin A. (Eds). Drug treatment of adult and child psychiatric disorders (1980), Williams and Wilkins, Baltimore 576-756
54. Spencer T.J., Biederman J., Wilens T., et al. Pharmacotherapy of attention deficit hyperactivity disorder across the lifecycle: a literature review. J Am Acad Child Adolesc Psychiatry 35 (1996) 409-432
55. Goldman L., Genel M., Bezman R., et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 279 (1998) 1100-1107
56. Quinn P.O., and Rapoport J.L. One-year follow-up of hyperactive boys treated with imipramine or methylphenidate. Am J Psychiatry 132 (1975) 241-245
57. Biederman J., Gastfriend D.R., and Jellinek M.S. Desipramine in the treatment of children with attention deficit disorder. J Clin Psychopharmacol 6 (1986) 359-363
58. Gastfriend D.R., Biederman J., and Jellinek M.S. Desipramine in the treatment of attention deficit disorder in adolescents. Psychopharmacol Bull 21 (1985) 144-145
59. Wilens T.E., Biederman J., Geist D.E., et al. Nortriptyline in the treatment of attention deficit hyperactivity disorder: a chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 32 (1993) 343-349
60. Garfinkel B.D., Wender P.H., Sloman L., et al. Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Adolesc Psychiatry 22 (1983) 343-348
61. Gittleman-Klein R. Pilot clinical trial of imipramine in hyperkinetic children. In: Conners C.K. (Ed). Clinical use of stimulant drugs in children (1974), Excerpta Medica, The Hague, Netherlands 192-201
62. Greenberg L., Yellin A., Spring C., et al. Clinical effects of imipramine and methylphenidate in hyperactive children. Int J Ment Health 4 (1975) 144-156
63. Rapoport J.L., Quinn P., Bradbard G., et al. Imipramine and methylphenidate treatment of hyperactive boys: a double-blind comparison. Arch Gen Psychiatry 30 (1974) 789-793
64. Gross M. Imipramine in the treatment of minimal brain dysfunction in children. Psychosomatics 14 (1973) 283-285
65. Huessy H., and Wright A. The use of imipramine in children's behavior disorders. Acta Paedopsychiatr 37 (1970) 194-199
66. Kupietz S.S., and Balka E.B. Alterations in the vigilance performance of children receiving amitriptyline and methylphenidate pharmacotherapy. Psychopharmacology 50 (1976) 29-33
67. Yepes L.E., Balka E.B., Winsberg B.G., et al. Amitriptyline and methylphenidate treatment of behaviorally disordered children. J Child Psychol Psychiatry 18 (1977) 39-52
68. Watter N., and Dreyfuss F.E. Modifications of hyperkinetic behavior by nortriptyline. Va Med Mon 100 (1973) 123-126
69. Werry J. Imipramine and methylphenidate in hyperactive children. J Child Psychol Psychiatry 21 (1980) 27-35
70. Winsberg B.G., Bialer I., Kupietz S., et al. Effects of imipramine and dextroamphetamine on behavior of neuropsychiatrically impaired children. Am J Psychiatry 128 (1972) 1425-1431
71. Gualtieri C.T., and Evans R.W. Motor performance in hyperactive children treated with imipramine. Percept Mot Skills 66 (1988) 763-769
72. Rapport M., Carlson G., Kelly K., et al. Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 32 (1993) 333-342
73. Biederman J., Baldessarini R.J., Wright V., et al. A double-blind placebo controlled study of desipramine in the treatment of attention deficit disorder: III. Lack of impact of comorbidity and family history factors on clinical response. J Am Acad Child Adolesc Psychiatry 32 (1993) 199-204
74. Cox W. An indication for the use of imipramine in attention deficit disorder. Am J Psychiatry 139 (1982) 1059-1060
75. Wilens T.E., Biederman J.B., Mick E., et al. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 183 (1995) 48-50
76. Dillon D.C., Salzman I.J., and Schulsinger D.A. The use of imipramine in Tourette's syndrome and attention deficit disorder: case report. J Clin Psychiatry 46 (1985) 348-349
77. Hoge S.K., and Biederman J. A case of Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine. J Clin Psychiatry 47 (1986) 478-479
78. Riddle M.A., Hardin M.T., Cho S.C., et al. Desipramine treatment of boys with attention-deficit hyperactivity disorder and tics: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 27 (1988) 811-814
79. Singer S., Brown J., Quaskey S., et al. The treatment of attention-deficit hyperactivity disorder in Tourette's syndromes: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 95 (1994) 74-81
80. Spencer T., Biederman J., Kerman K., et al. Desipramine in the treatment of children with tic disorder or Tourette's syndrome and attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 32 (1993) 354-360
81. Spencer T., Biederman J., Wilens T., et al. Nortriptyline in the treatment of children with attention deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 32 (1993) 205-210
82. Abramowicz M. Sudden death in children treated with a tricyclic antidepressant. In: The medical letter on drugs and therapeutics. New Rochelle, NY: The Medical Letter; 1990. p. 53.
83. Biederman J., Baldessarini R.J., Wright V., et al. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28 (1989) 777-784
84. Casat C.D., Pleasants D.Z., Schroeder D.H., et al. Bupropion in children with attention deficit disorder. Psychopharmacol Bull 25 (1989) 198-201
85. Casat C.D., Pleasants D.Z., and Van Wyck Fleet J. A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmacol Bull 23 (1987) 120-122
86. Conners K., Casat C., Gualtieri T., et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 35 (1996) 1314-1321
87. Barrickman L., Perry P., Allen A., et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34 (1995) 649-657
88. Barrickman L., Noyes R., Kuperman S., et al. Treatment of ADHD with fluoxetine: a preliminary trial. J Am Acad Child Adolesc Psychiatry 30 (1991) 762-767
89. NIMH. Alternative pharmacology of ADHD, 1996.
90. Adler L., Resnick S., Kunz M., et al. Open-label trial of venlafaxine in attention deficit disorder (1995), New Clinical Drug Evaluation Unit Program, Orlando
91. Findling R., Schwartz M., Flannery D., et al. Venlafaxine in adults with ADHD: an open trial. J Clin Psychiatry 57 (1996) 184-189
92. Hornig-Rohan M., and Amsterdam J. Venlafaxine vs. stimulant therapy in patients with dual diagnoses of ADHD and depression (1995), New Clinical Drug Evaluation Unit Program, Orlando (FL) -pp. Poster #92
93. Reimherr F., Hedges D., Strong R., et al. An open-trial of Venlaxine in adult patients with attention deficit hyperactivity disorder (1995), New Clinical Drug Evaluation Unit Program, Orlando (FL)
94. Nemeroff C., DeVane L., and Pollock B. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153 (1996) 311-320
95. Spencer T., Biederman J., Wilens T., et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155 (1998) 693-695
96. Spencer T., Biederman J., Heiligenstein J., et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11 (2001) 251-265
97. Spencer T., Heiligenstein J., Biederman J., et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63 (2002) 1140-1147
98. Michelson D., Faries D., Wernicke J., et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108 (2001) E83
99. Kratochvil C.J., Bohac D., Harrington M., et al. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11 (2001) 167-170
100. Spencer T., Newcorn J., Kratochvil C., et al. Effects of atomoxetine on growth after 2-year treatment in pediatric patients with ADHD. Pediatrics 116 (2005) e74-e80
101. Heil S.H., Holmes H.W., Bickel W.K., et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67 (2002) 149-156
102. Engber T.M., Koury E.J., Dennis S.A., et al. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett 241 (1998) 95-98
103. Myrick H., Malcolm R., Taylor B., et al. Modafinil: preclinical, clinical, and post-marketing surveillance-a review of abuse liability issues. Ann Clin Psychiatry 16 (2004) 101-109
104. Swanson J.M., Greenhill L.L., Lopez F.A., et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 67 1 (2006) 137-147
105. Biederman J., Swanson J.M., Wigal S.B., et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 116 6 (2005) e777-e784
106. Leckman J.F., Hardin M.T., Riddle M.A., et al. Clonidine treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 48 (1991) 324-328
107. Hunt R.D., Capper L., and O'Connell P. Clonidine in child and adolescent psychiatry. J Child Adolesc Psychopharmacol 1 (1990) 87-102
108. Prince J., Wilens T., Biederman J., et al. Clonidine for ADHD related sleep disturbances: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 35 (1996) 599-605
109. Chappell P., Riddle M., Scahill L., et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 34 (1995) 1140-1146
110. Horrigan J.P., and Barnhill L.J. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 5 (1995) 215-223
111. Hunt R., Arnsten A., and Asbell M. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34 (1995) 50-54
112. Gunning B. A controlled trial of clonidine in hyperkinetic children. Thesis: Department of Child and Adolescent Psychiatry. Academic Hospital Rotterdam- Sophia Children's Hospital Rotterdam. The Netherlands. Rotterdam, The Netherlands, Department of Child and Adolescent Psychiatry. Academic Hospital Rotterdam- Sophia Children's Hospital Rotterdam, 1992.
113. Hunt R.D. Treatment effects of oral and transdermal clonidine in relation to methylphenidate: an open pilot study in ADD-H. Psychopharmacol Bull 23 (1987) 111-114
114. Hunt R.D., Minderaa R.B., and Cohen D.J. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 24 (1985) 617-629
115. Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58 (2002) 527-536
116. Steingard R., Biederman J., Spencer T., et al. Comparison of clonidine response in the treatment of attention deficit hyperactivity disorder with and without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 32 (1993) 350-353
117. Scahill L., Chappell P.B., Kim Y.S., et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 158 (2001) 1067-1074
118. Taylor F.B., and Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 21 2 (2001) 223-228
119. Wilens T.E., and Spencer T.J. Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry 38 (1999) 614-622
120. Biederman J., Melmed R.D., Patel A., et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 121 1 (2008) e73-e84
121. Faraone S.V., Biederman J., Spencer T.J., et al. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed 8 (2006) 4
122. Banaschewski T., Coghill D., Santosh P., et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15 (2006) 476-495